Article info

Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial

Authors

  1. Correspondence to Dr Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA; janowitz{at}cshl.edu
View Full Text

Citation

Brennan CM, Nadella S, Zhao X, et al
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial

Publication history

  • Received January 11, 2022
  • Accepted January 25, 2022
  • First published February 10, 2022.
Online issue publication 
April 08, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.